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Summary
Background Hypertension is one of the commonest diseases worldwide. Its prevalence is estimated to approximately 
25% of the population. In addition, hypertension is an important risk factor for increased cardiovascular events. 
In most cases it is of idiopathic origin, but may also be due to another disease, e.g. endocrine dysfunction. Primary 
aldosteronism (PA) is a common cause of resistant hypertension; its proper diagnosis determines further therapy. 
The aim of this study was to evaluate the prevalence of PA in a group of 350 patients (240 women and 110 men) 
with hypertension. 
Material and method All patients underwent hormonal tests including assessment of the levels of: ACTH, cortisol 
(baseline and in dexamethasone suppression test), DHEA-S, chromogranin A, VMA urine excretion, aldosterone 
and active renin. Afterwards, an intravenous load test with 0.9% neutral saline solution was performed. Abdominal 
ultrasound was performed in all patients, and abdominal computed tomography only in patients with abnormal 
hormonal tests. Other forms of secondary hypertension were previously excluded.
Results Primary aldosteronism was diagnosed in 58 patients (16.6%) — 38 women and 20 men. Adrenal adeno-
ma was found in 20 patients (34.5%), and idiopathic hyperaldosteronism in 38 patients (65.5%). Hypokalaemia 
occurred in 25 patients (43.1%). Moreover, it was found that the aldosterone-renin ratio above 8.25 supports the 
diagnosis of PA. 
Conclusion We conclude that the diagnosis of PA should not be limited only to the hypertensive patient with hy-
pokalaemia. PA is an important cause of hypertension, especially among patients with difficulties in normalization 
of blood pressure with standard pharmacological treatment.
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Background
Hypertension is one of the most frequently diag-
nosed diseases worldwide. Two large projects started 
the analysis of the epidemiology of hypertension: the 
Framingham study population and the Seven Coun-
tries Study. The prevalence of high blood pressure 
was estimated to approximately 25% of the popu-
lation [1, 2]. The prevalence of hypertension varies 
depending on the geographical, socio-cultural and 
economic factors. Some other studies have shown 
that the incidence of hypertension depends on the 
age and diet and ranged from 3.4% to 68.9% among 
men and from 6.8% to 72.5% in women [3, 4]. In 
the population of Africa and the underdeveloped 
south of China prevalence of hypertension does not 
exceed 15%, in Western Europe and the US white 
population is moderate and around 15–30%, while 
in Poland, Russia, Finland and among African Ame-
ricans in the United States is estimated approximate-
ly to 30% [5].
The most recent Polish multicentre national proj-
ect WOBASZ enrolled 13 545 subjects (6392 men 
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and 7153 women), aged 20–74 years. The average 
incidence of hypertension in Poland was about 36%. 
Hypertension was higher in men (42.1%) than in 
women (32.9%) [6].
High blood pressure is considered as one of the 
most important risk factors for cardiovascular events 
such as coronary artery disease, heart failure and 
intracerebral stroke. These conditions are the main 
causes of death, morbidity and disability in Poland, 
other European countries and the United States [1].
The largest meta-analysis of Lewington [1] and 
MacMahon [2] showed an increased risk of cardiovas-
cular disease above 115/75 mmHg. Moreover, every 
5 mmHg elevation in diastolic blood pressure is related 
to increased risk of stroke by 34% and coronary artery 
disease by 21% [2]. According to Lewington et al. [1], 
the rise in systolic blood pressure of 20 mmHg and/ 
/or diastolic blood pressure of 10 mmHg more than 
doubles the risk of death from brain stroke, ischaemic 
heart disease and other vascular causes. 
In most cases hypertension is of idiopathic but 
may also be due to another disease such as renal 
structure or vascular disturbances or endocrine dys-
function. The main goal of the diagnosis of hyper-
tension is secondary high blood pressure detection 
because this determines further therapy. 
Goal
The aim of this study was to evaluate the preva-
lence of primary aldosteronism in a group of 350 pa-
tients (240 women and 110 men) with hypertension. 
Material and methods
All patients underwent hormonal tests including 
assessment of the levels of: ACTH, cortisol (baseline 
and in dexamethasone suppression test), DHEA-S, 
chromogranin A, VMA urine excretion, aldosterone 
and active renin. Afterwards an intravenous load 
test with 0.9% neutral saline solution (2.0 l within 
4 hours) was performed. The concentration of active 
renin was measured by radioimmunoassay method 
and aldosterone by RIA technique. Abdominal ultra-
sound was performed in all patients, and abdominal 
computed tomography only among patients with 
abnormal hormonal tests. Other forms of secondary 
hypertension were previously excluded.
Results
Primary aldosteronism was diagnosed in 58 pa-
tients (16.6%) — 38 women and 20 men. Adrenal 
adenoma was found in 20 patients (34.5%), and id-
iopathic hyperaldosteronism in 38 patients (65.5%). 
Hypokalaemia occurred in 25 patients (43.1%). In 
addition, it was found that the aldosterone-renin 
ratio above 8.25 supports the diagnosis of primary 
aldosteronism. The results suggest that primary al-
dosteronism seems to be one of the most common 
causes of secondary hypertension. The dominant 
group of patients was those with an idiopathic aldo-
steronism without hypokalaemia. Data were statisti-
cally analysed using MS Office Excel and Statistica 
Software. Data are shown in Table I and II.
Discussion
The history of primary aldosteronism (PA) is not 
so long and has only 61 years. The first description of 
coincidence of an adrenal cortical tumour and hyper-
tension was published in 1953 by the Polish doctor 
Table I. Characteristic of study group
n (%)
Total number of patients, including: 350 100
Women 240 68.6
Men 110 31.4








With hypokalaemia 25 43.1*
*for a group of patients with hyperaldosteronism
Table II. Concentration of potassium, aldosterone and active renin
Parameter Mean ± SD Range Normal values
Potassium [mmol/l]  3.75 ± 0.62  2.77 –5.22  3.5 –5.5
Aldosterone [ng/dl]  77.6 ± 30.54  22.4 –180.3  4 –31
Active renin [pg/ml]  2.88 ± 2.65  0.0 –9.4  3.6 –65.6
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Michał Lityński [7]. Unfortunately, the results of 
his work were not complete because of impossibility 
in determination of the level of aldosterone. Only 
two years after the Lityński’s publication Jerome 
W. Conn proved that increased secretion of aldoste-
rone by the adrenal zona glomerulosa is responsible 
for high blood pressure [8]. 
Most commonly PA is due to bilateral adrenal 
hyperplasia (BAH) of zona glomerulosa; less frequent 
is an aldosterone producing adenoma (APA) — clas-
sic Conn’s syndrome [9]. Other cause of PA are 
even more rare, such as cancer (about 1%), ectopic 
secretion of aldosterone (approx. 1%), family aldo-
steronism (about 1%) or unilateral nodular adrenal 
hyperplasia (approx. 1%) (the so-called 1% rule) 
[10]. Recently, in approximately 50% of patients 
with APA specific genetic alteration have been de-
tected [9]. 
The incidence of PA among hypertensive patients 
is usually estimated around 6–13% [11–13]. How-
ever, a 10% prevalence of PA was found among 
hypertensive patients in prospective studies, and this 
figure raised to around 30% when aldosterone–renin 
ratio (ARR) was used as a screening test by general 
practitioner [9]. 
Gordon et al. (1994) in one of the most impor-
tant reports found PA in 8.5% of 199 patients with 
normokalaemic hypertension [14].
Eide et al. (1996) recognized PA as a cause of high 
blood pressure in 23% among patients with refracto-
ry hypertension [15]. Gallay et al. (2001) found PA 
in a group of 17% patients [16]. 
The Czech authors [17] analysed cases of secon-
dary hypertension in a group of 402 patients, the 
most common was PA (19%), while the incidence of 
pheochromocytoma was 5% and renal-vascular hy-
pertension 4.5%, hypercortisolism and renal disease 
were less than 3% of diagnoses.
Omura et al. (2004) found PA in 6% of Japanese 
hypertensive patients [18]. The multicentre study in-
volving five continents [19] showed a higher frequen-
cy of PA than previously thought. It was found that 
PA is responsible for 8–14% of cases of hypertension, 
only 10–37% with hypokalaemia. Adrenal adenoma 
was found in 10–30% of patients.
Rossi et al. (2006) confirmed PA in 11.2% pa-
tients, around 6.4% had idiopathic PA; adrenal ade-
noma was diagnosed only in 4.8% of patients [16].
The RESIST-POL study conducted in the years 
2009–2012 in the Department of Hypertension, the 
Institute of Cardiology, Warsaw, enrolled 204 pa-
tients with resistant hypertension. Primary aldoste-
ronism was found in 16% of patients [20].
It is worth to say that after almost 10 years after 
the description of the “classical” phenotype of pri-
mary aldosteronism, Conn estimated that approxi-
mately 20% of patients with hypertension may have 
adrenal adenoma and hyperaldosteronism [21].
In our study, we found that PA is responsible for 
16.6% cases of hypertension (more frequent than the 
average), moreover 65% of PA was of idiopathic origin. 
In our study, hypokalaemia occurred only in 23 
patients (42%). This finding is consistent with the 
observations of Conn in 1965 [22] and other authors 
[23, 24] who presented data where hypokalaemia was 
found in only 30–40% of patients with PA, and was 
mostly observed in patients with a single adenoma. 
Aldosteronoma was found in only 20–40% of 
patients with PA. These patients usually presented 
the classic phenotype of Conn’s syndrome including 
hypertension, hypokalaemia [25, 26]. PA caused by 
bilateral adrenal hyperplasia is estimated at approxi-
mately 60%. In our work the adrenal adenoma was 
found in 35%. 
According to Gordon et al. (2007), screening for 
PA should be performed in all patients with hyper-
tension — including those without hypokalaemia 
and without positive family history [27]. Delay in 
diagnosis of PA can lead to irreversible consequences. 
Incorrect treatment reduces the chance of obtaining 
normal blood pressure.
The wide variation of the ARR cut-offs com-
plicates the diagnostic criteria and choice of “gold 
standard” test to definitely confirm or exclude PA. 
Although determining the rate of ARR is considered 
to be the most reliable method of screening for PA, 
its interpretation is complex and requires individu-
al assessment of the impact of various factors that 
may affect the renin-angiotensin-aldosterone system 
(RAAS). To reduce the proportion of both false posi-
tive rates and false negative, it is essential to eliminate 
the effects negative factors affecting the RAAS. The 
estimation specificity of ARR varies from 71–84% 
with sensitivity ranging from 73% to 93%, whereas 
the prevalence of PA was found to be 13% [9].
In contrast, Young (1997) suggested that for the 
initial diagnosis of PA, in addition to the ARR above 
20, another necessary criterion is the level of aldo-
sterone higher than 15 ng/dL [28]. This condition 
of established diagnosis of PA was met in 90% of 
Mayo Clinic patients with confirmed adrenal ade-
noma [29].
Some authors found that 47% of patients suffer-
ing from PA had ARR above 30 [30] (usually taken 
as the cut-off level) and 28% of those patients had 
ARR above 50 [31]. In our study it was found that 
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the ARR above 8.25 supports the diagnosis of pri-
mary aldosteronism. It should be emphasized that 
we used active renin concentration instead of plasma 
renin activity.
Conclusion
It is widely known that the prevalence of PA is 
higher than previously believed. We conclude that 
the diagnosis of primary aldosteronism should not 
be limited only to the patient with high blood pres-
sure and hypokalaemia. Primary aldosteronism is an 
important cause of hypertension, especially among 
patients with difficulties in normalization of blood 
pressure with standard pharmacological treatment. 
Delay in establishing the diagnosis may affect the 
response to treatment and overall prognosis. 
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